Transforming growth factor ␤-activated kinase 1 (TAK1) functions downstream of inflammatory cytokines to activate c-Jun N-terminal kinase (JNK) as well as NF-B in several cell types. However, the functional role of TAK1 in an in vivo setting has not been determined. Here we have demonstrated that TAK1 is the major regulator of skin inflammation as well as keratinocyte death in vivo. Epidermal-specific deletion of TAK1 causes a severe inflammatory skin condition by postnatal day 6 -8. The mutant skin also exhibits massive keratinocyte death. Analysis of keratinocytes isolated from the mutant skin revealed that TAK1 deficiency results in a striking increase in apoptosis in response to tumor necrosis factor (TNF). TAK1-deficient keratinocytes cannot activate NF-B or JNK upon TNF treatment. These results suggest that TNF induces TAK1-deficient keratinocyte death because of the lack of NF-B (and possibly JNK)-mediated cell survival signaling. Finally, we have shown that deletion of the TNF receptor can largely rescue keratinocyte death as well as inflammatory skin condition in epidermal-specific TAK1-deficient mice. Our results demonstrate that TAK1 is a master regulator of TNF signaling in skin and regulates skin inflammation and keratinocyte death.
TAK1
2 (transforming growth factor ␤-activated kinase 1) is a member of the mitogen-activated protein kinase kinase kinase family and is activated by inflammatory cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) and Toll-like receptor ligands (1, 2) . In IL-1, TNF, and Toll-like receptor ligand signaling pathways, TAK1 has been shown to be an essential signaling intermediate that functions upstream of IB kinase (IKK)-NF-B and c-Jun N-terminal kinase (JNK) in B cells and some culture cells (3) (4) (5) . However, the role of TAK1 has not been established in an in vivo context due to embryonic death of TAK1 germ line knock out (3, 4) .
Skin homeostasis is maintained through a well balanced interplay of cytokines and growth factors (6) . Several cytokines, including TNF, activate JNK and NF-B pathways (7, 8) that play critical roles in epidermal homeostasis involving skin inflammation and cancer development (9 -16) . Inactivation of IKK␤ or IKK␥, which blocks the so-called canonical NF-B pathway, produces a severe inflammatory skin condition. Furthermore, NF-B hypofunction is implicated in epidermal squamous cell carcinoma. In contrast, activation of JNK pathway is involved in epidermal hyperplasia and subsequent cancer development (14, 15) . Roles of IKK-NF-B and JNK in skin have been demonstrated by using genetic and pharmacological inhibitory approaches (12, 14, 15) . However, the upstream regulators of NF-B and JNK pathways in skin have not yet been determined. In this study, we generated and characterized mice with epidermal-specific deletion of TAK1. We found that TAK1 is an essential intermediate in TNF signaling to activate both IKK and JNK in keratinocytes. TAK1 deficiency causes severe dysregulation of skin homeostasis. Our results suggest that the dysregulation in TAK1 mutant skin is mediated by TNF-induced keratinocyte death.
EXPERIMENTAL PROCEDURES

Mutant Mice-To generate K5CreTAK1
FL/FL mice, mice carrying a floxed Map3k7 allele (TAK1
FL/FL
) (mixed background of C57BL/6 and 129/SvJ) (3) were crossed to transgenic mice expressing the Cre recombinase under the control of the keratinocyte-specific keratin 5 promoter (K5Cre) (mixed background of C57LBL/6 and DBA/2J) (17) . TNFR1-deficient mice C57BL/6 Tnfrsf1a tm1Mak (TNFR1 Ϫ/Ϫ ) (18) were obtained from The Jackson Laboratory.
Histology and Immunohistochemistry-Sections were stained with hematoxylin and eosin for histological analysis. Immunohistochemical analysis was performed on paraffin. Bound antibodies were visualized by diaminobenzidine, and sections were counterstained with hematoxylin. dUTP nick-end labeling (TUNEL) assay was performed on paraffin sections using an apoptotic cell death detection kit (Promega) according to the manufacturer's instructions. Polyclonal antibody against TAK1 described previously (2), polyclonal antibodies against K5, K6, K10, loricrin, involucrin, filaggrin (Convance), IB-␣, JNK1 (FL) (Santa Cruz), caspase 3 (Cell Signaling), and phospho-JNK (Thr-183/Tyr-185) (Cell Signaling) or monoclonal antibody against ␤-actin (Sigma) were used. Immunofluorescence was performed on frozen sections using polyclonal antibody against TAK1 along with monoclonal antibody against nidogen (Chemicon). Bound antibodies were visualized by Cy2-or Cy3-conjugated secondary antibodies.
Cell Culture-Primary and spontaneously immortalized keratinocytes derived from the skin of P0 -2 mice were cultured in Ca 2ϩ -free Eagle's minimal essential medium (BioWhittaker) supplemented with 4% Chelex-treated bovine growth serum, 10 ng/ml of human epidermal growth factor (Invitrogen), 0.05 mM calcium chloride, and 1% penicillin-streptomycin at 33°C in 8% CO 2 . Murine primary fibroblasts derived from the dermis of P0 -2 mice were cultured in Dulbecco's modified Eagle's medium supplemented with 10% bovine growth serum at 37°C in 5% CO 2 .
Cytotoxicity Assays-Keratinocytes were treated with recombinant human TNF-␣, mouse IL-1␤, human transforming growth factor ␤1 (TGF-␤1) (Roche Diagnostics), or lipopolysaccharide (Sigma) for 24 h. The viable adherent cells were stained with 0.1% crystal violet. The stain was solubilized by adding 50% ethanol containing 0.1 M sodium citrate, and the absorbance of each plate was determined at 595 nm.
Real-time PCR Analysis-Total RNA was prepared from skin or culture keratinocytes using the RNeasy protect mini-kit (Qiagen). cDNA was synthesized using TaqMan reverse transcription reagents (Applied Biosystems). Real-time PCR analysis was performed using the ABI PRISM 7000 sequence detection system. An Assays-on-Demand gene expression kit (Applied Biosystems) was used. All samples were normalized to the signal generated from glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
RESULTS
TAK1 is expressed in both the dermis and epidermis (Fig.  1a) . To investigate the role of TAK1 in epidermis in vivo, we have generated and characterized mice carrying an epidermal-specific deletion of TAK1. The mice were generated by crossing TAK1 floxed mice (TAK1 FL/FL ) (3) with a mouse line expressing Cre under the control of the epidermal-specific keratin 5 (K5) promoter (K5Cre transgenic mice) (17) . In this system, Cre deletes exon 2 (amino acids 41-77) of mouse TAK1, which contains an ATP binding site, and a truncated/kinase-dead version of TAK1 (TAK1⌬) is generated in K5-expressing cells, while wild-type TAK1 is expressed in other cell types. TAK1⌬ was expressed in keratinocytes isolated from K5CreTAK1 FL/FL mice, whereas wild-type TAK1 was detected in dermal fibroblasts from the same mice, indicating that TAK1 is specifically deleted in epidermis (Fig. 1b) .
K5CreTAK1 FL/FL mice were born at the expected Mendelian ratios and were grossly indistinguishable from control genotype littermates from birth until postnatal day 2-3 (P2-3) (Fig. 2a) . However, by P7, the K5CreTAK1 FL/FL mice showed a strong cutaneous phenotype characterized by hard, inflexible skin and widespread scaling (Fig. 2a) . ␤-actin was used as a loading control, and K5 was used as a keratinocyte marker. Schematic drawing shows structure of TAK1⌬.
P7 revealed a progressive epidermal condition involving severe apoptosis, hyperkeratosis, inflammation, and eventually epidermal erosion in K5CreTAK1 FL/FL mice ( Fig. 2b and Table 1 ).
Mutant epidermis at P0 resembled normal P0 epidermis; however, by P1 numerous keratinocytes with dark pyknotic nuclei, eosinophilic cytoplasm, and absence of cellular con- tacts were present in the mutant epidermis (Fig. 2b, arrow) . This staining pattern and cellular morphology is indicative of apoptotic keratinocytes. On P3 there were many more apoptotic basal and suprabasal keratinocytes, and hyperkeratosis was prominent. The mutant epidermis appeared highly disorganized because of keratinocyte hypertrophy, keratinocyte depletion due to apoptosis, and the presence of immune cells in intraepidermal microabscesses as well as occasional sebocytes in the epidermis (Fig. 2b, bottom  panel) . On P7 the epidermis was hyperplastic, hypertrophic, and severely hyperkeratotic, and areas of complete epidermal erosion accompanied by severe inflammation were common. Immune cells infiltrated into the epidermis and were found in intraepidermal microabscesses as well as embedded in the thickened hyperkeratotic stratum corneum. Sebocytes were also present in the epidermis (Fig. 2b, right column) . This inflammatory condition is somehow similar to skin with epidermal-specific deletion of IKK␤ or IKK␥ (11, 16) . However, this pronounced apoptotic phenotype has not been reported either in mutant skin with deletion of IKK␤ or IKK␥ (11, 16) or with inactivation of NF-B (13, 14) .
To further characterize the phenotypes of epidermal TAK1 deletion, we conducted histological and molecular analyses of mutant skin at several time points after birth. We examined the expression of epidermal differentiation markers, K5 (basal layer marker), K10 (suprabasal marker), and loricrin (granular layer marker) (Fig. 3a) . These marker proteins were expressed with a normal distribution at P0 but became slightly abnormal at P1. At P3, even though the mutant mice showed only minor macroscopic differences from their control littermates (Fig. 2a) , expression of the keratinocyte differentiation markers K10 and loricrin was markedly reduced, indicating that the keratinocyte differentiation program was altered. Instead of keratins indicative of normal epidermis, the hyperproliferative/wound-associated keratin 6 (K6) was highly induced in mutant skin at P3 (Fig.  3b, upper panel) . This alteration of cytoskeleton composition resembles that in wound edge or skin with inflammatory disease, in which the normal set of keratins are replaced with hyperproliferative/wound-associated keratins. We also conducted a genome-wide gene expression study using microarrays and RNA isolated from K5CreTAK1 FL/FL mutant and K5CreTAK1 FL/ϩ control epidermis (supplemental Table S1 ). The expression of many wound-associated keratins, S100 proteins, gap junction proteins, and cytokines was dramatically changed in the epidermal-specific TAK1 deletion mice. Thus, these mice display the hallmarks of wounded and inflamed skin. We quantified the expression of several cytokines and wound-associated proteins by real-time PCR. We found that IL-1, macrophage inflammatory protein-2 (MIP-2; IL-8 in human), S100A9, and wound-associated keratin of K16 were highly overexpressed in mutant skin at P3 (Fig. 3c) . These results collectively suggest that by P3 the epidermal TAK1 deletion produces a phenotype in the epidermis that is similar to wounding.
Our histological analysis suggests an increased number of apoptotic keratinocytes in mutant epidermis (Fig. 2b) . Therefore, we next examined apoptosis by TUNEL staining and immunohistochemical staining of activated caspase 3 (Fig. 3b,  middle and bottom panels) . Both demonstrated the presence of massive numbers of apoptotic keratinocytes in the mutant epidermis at P3 and P7. These results demonstrate that TAK1 is essential for skin homeostasis and is involved in both inflammation and keratinocyte survival.
To begin to identify the molecular events that initiate this phenotype, we analyzed keratinocytes isolated from K5CreTAK1
FL/FL
and TAK1 FL/FL (control) mice. We anticipated that the mutant phenotype would be caused by a keratinocyte intrinsic defect. We found that TAK1-deficient keratinocytes could proliferate at a slightly slower rate than the control keratinocytes ( Fig. 4a) and were able to terminally differentiate, as demonstrated by expression of involucrin and filaggrin (Fig. 4b ). These results demonstrate that TAK1 is not essential for keratinocyte proliferation or differentiation, suggesting that the phenotype of K5CreTAK1 FL/FL is not due to a defect in proliferation or differentiation of TAK1-deficient keratinocytes. Expression of IL-1, MIP-2, S100A9, or K16 was not elevated in TAK1-deficient keratinocytes (Fig. 4c) . This suggests that the up-regulation of these gene products in mutant skin (Fig. 3c ) occurs in other cell types or in TAK1-deficient keratinocytes activated by stimuli from other cell types. Therefore, IL-1, MIP-2, S100A9, or K16 is not directly upregulated by TAK1 deficiency.
We next examined TNF and IL-1 signaling pathways in TAK1-deficient keratinocytes. In wild-type keratinocytes, TNF and IL-1 induced the activation of JNK and degradation of IB. However, in TAK1-deficient keratinocytes, TNF-and IL-1-induced activation of JNK and degradation of IB was largely impaired (Fig. 4d) , which is similar to that observed in TAK1-deficient mouse embryonic fibroblasts (3, 4). Because we observed massive apoptosis in TAK1-deficient epidermis (Fig. 3b) , we next examined apoptosis in mutant and control keratinocytes in culture. TAK1 plays an important role in TNF, IL-1, TGF-␤, and Toll-like receptor signaling pathways, all of which have been reported to mediate cell death in some cell types (19 -22) . Therefore, we examined cell viability following treatment with TNF, IL-1, TGF-␤, and lipopolysaccharide (Fig. 4e) . We observed that only TNF could induce cell death in TAK1-deficient keratinocytes, whereas control keratinocytes were absolutely resistant. TNF treatment activated caspase 3 in TAK1-deficient but not in control keratinocytes (Fig. 4f ) . TNF was expressed in wild-type as well as mutant skin, and the levels of expression were similar in both skin samples (supplemental Fig. S1 ). These results led us to speculate that TAK1-deficient keratinocytes are killed by low levels of TNF expressed under normal skin conditions, which may underlie the epidermal phenotype caused by TAK1 deletion. To verify the idea that TNF-induced cell death is the cause of the phenotype of TAK1-deficient epidermis, we generated double-mutant deletions of the TNF receptor I (TNFRI) (18) ). The mice with the double mutations grew normally and did not develop severe skin disease (Fig. 5, a and b) . Importantly, apoptotic keratinocytes were not detected over a large area in the double-mutant skin (Fig. 5c) . Expression of IL-1, MIP-1, S100A9, and K16 was also marginally detected in most of the skin samples from the double-mutant mice (Fig. 5d ). These results demonstrate that TNF is a major cause of inflammatory skin disease in TAK1-deficient epidermis. However, some double-mutant mice developed several inflamed plaques (Fig. 5a ). Histological analysis revealed that the double-mutant skin was normal except for those plaques (Fig. 5, b and c) . The inflamed small plaques in some double-mutant mice showed the same dysregulation as that in epidermal-specific TAK1 mutants at P5 (Fig. 5, b and c) . Expression of IL-1, MIP-1, S100A9, and K16 was increased in these affected mice at P5 (Fig. 5d) . TNF family cytokines such as TNF-related apoptosis-inducing ligand (TRAIL) may be involved in this minor dysregulation. The inflamed plaques and expression of inflammation markers disappeared shortly, and the double-mutant mice were grossly normal by P25 (Fig. 5, a  and d ) . From these results, we conclude that TNF causes cell death in TAK1-deficient keratinocytes, which in turn stimulates inflammatory responses. Because TNF always resides at some levels in the skin, cell death is induced constitutively in TAK1-deficient epidermis; this causes the prolonged activation of inflammatory responses, which results in a skin condition similar to chronic inflammatory diseases.
DISCUSSION
In this study, we found that mice carrying epidermal-specific deletion of TAK1 gene develop severe skin inflammation, and we attempted to determine the cause of this phenotype. We have demonstrated that (i) TAK1-deficient keratinocytes are normal in proliferation and differentiation; (ii) TAK1 deficiency causes impaired activation of NF-B and JNK in response to TNF; (iii) TNF induces apoptosis in TAK1-deficient keratinocytes, whereas wild-type keratinocytes are abso- Ϫ/Ϫ (CT ) and K5CreTAK1FL/FLTNFR1 Ϫ/Ϫ (MT ) skin at P5 or P25 (n, 9 -11 for P5; n, 4 for P25). Real-time PCR analysis was performed to quantify the indicated gene expression. Results were analyzed using the comparative Ct Method. Relative mRNA levels were calculated using CT mRNAs as base lines.
lutely resistant to TNF killing. Finally, we found that deletion of TNF signaling rescues the skin phenotype of TAK1 deletion. Therefore, we propose that TNF-induced cell death due to the lack of NF-B/JNK pathways is the cause of skin inflammation in epidermis-specific TAK1 deletion mice.
The effect of TAK1 deletion on sensitivity to TNF-induced cell death is much greater than those of IKK␥ and IKK␤ deletions (23) (24) (25) . Why does the deletion of TAK1 make keratinocytes extremely sensitive to TNF? There is no detectable change in p53 status or DNA damage in TAK1-deleted skin in vivo or in TAK1-deficient keratinocytes (data not shown). It is possible that, upon TNF treatment, TAK1 mediates multiple anti-apoptotic signaling pathways in addition to the NF-B pathway. In TAK1-deficient keratinocytes, TNF-and IL-1-induced activation of JNK is abrogated. Although the JNK pathway has been implicated in pro-apoptotic signaling through several different mechanisms such as modulation of Bcl-2 family proteins (8) , it has also been demonstrated that lack of JNK pathway impairs TNF-dependent anti-apoptotic protein expression and increases sensitivity to TNF killing (26) . The combined lack of both the NF-B and JNK pathways in TAK1-deficient keratinocytes may lead to hypersensitivity to TNFinduced cell death.
Our results demonstrate that TAK1 is the major mediator of TNF signaling in epidermis regulating the canonical NF-B as well as JNK pathways and that TAK1 deletion dramatically enhances TNF-induced keratinocyte death. TNF can induce apoptosis in many cell types through its caspase cascades; however, NF-B (and possibly JNK) pathway usually masks this TNF killing function (19) . Furthermore, TNF is known to function to promote tumor development and progression in various cancers, including skin cancer (27, 28) . Expression of genes activated by the NF-B and JNK pathways, such as cytokines, chemokines, proteases, and anti-apoptotic proteins, is likely to promote tumor development and progression. Because TAK1 is essential for both NF-B and JNK pathways, but does not affect TNF-induced caspase cascades, inhibition of TAK1 may reduce the tumor-promoting function of TNF and induce cell death. In addition, it has been demonstrated that selective ablation of the NF-B pathway in keratinocytes can moderately increase keratinocyte apoptosis but also results in the spontaneous development of skin cancer (12, 15) . This tumor development is abrogated by deletion of TNFR1 or inhibition of JNK, which suggests that TNF-induced JNK activation in the absence of NF-B pathway promotes skin carcinogenesis. Our results demonstrate that inhibition of TAK1 abolishes both the NF-B and JNK pathways and suggest that TAK1 may be an effective target to treat skin cancer.
